Prodrugs for improved CNS delivery

Advanced Drug Delivery Reviews

Volumn 19, Issue 2, 1996, Pages 171-202

  Anderson, Bradley D ^a  

^a UNIVERSITY OF UTAH   (United States)

Author keywords

Blood brain barrier; CNS; Prodrug

Indexed keywords

BIOCONVERSION; BIOLOGICAL MEMBRANES; BLOOD; BLOOD VESSELS; BRAIN; CELLS; CHEMICAL ACTIVATION; DRUG THERAPY; ENZYMES; LIPIDS;

CENTRAL NERVOUS SYSTEMS; DRUG LIPOPHILICITY; ENDOTHELIAL CELLS; LIPID BILAYER MEMBRANES; PRODRUGS;

DRUG PRODUCTS;

ADENOSINE DEAMINASE; AMINE OXIDASE (FLAVIN CONTAINING); CARRIER PROTEIN; CHLORMETHINE; CHOLESTEROL ESTER; DEXAMETHASONE; DIDANOSINE; ESTERASE; FOSCARNET; IDOXURIDINE; MELPHALAN; MILACEMIDE; OXIDOREDUCTASE; PHOSPHODIESTERASE; PRODRUG; THIORPHAN; VALPROIC ACID; ZIDOVUDINE;

BIOTRANSFORMATION; BLOOD BRAIN BARRIER; BRAIN MICROCIRCULATION; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG METABOLISM; DRUG TARGETING; ENZYME ACTIVATION; HYDROPHOBICITY; LIPID BILAYER; LIPOPHILICITY; PHARMACEUTICS; PHARMACOKINETICS; PRIORITY JOURNAL; REVIEW; TIGHT JUNCTION; TRANSCYTOSIS;

EID: 0343724706     PISSN: 0169409X     EISSN: None     Source Type: Journal    
DOI: 10.1016/0169-409X(95)00106-H     Document Type: Review

References (277)

1. Neuwelt, E.A. (1990) Implications of the Blood-Brain Barrier and Its Manipulation, Plenum Press, New York.
2. Pardridge, W.M. (1991) Peptide Drug Delivery to the Brain, Raven Press, New York.
3. Pardridge, W.M. (1993) Brain Drug Delivery and Blood-brain Barrier Transport. Drug Deliv. 1, 83-101.
4. Pardridge, W.M. (1993) The Blood-Brain Barrier: Cellular and Molecular Biology, Raven Press, New York.
5. Rapoport, S.I. (1976) Blood-Brain Barrier in Physiology and Medicine. Raven Press, New York.
6. Rapoport, S.I., Ohno, K. and Pettigrew, K.D. (1979) Drug entry into the brain. Brain Res. 172, 354-359.
7. Bradbury, M.W.B. (1992) Physiology and Pharmacology of the Blood-Brain Barrier, Springer-Verlag, Berlin.
8. Drewes, L.R. and Betz, A.L. (1993) Frontiers in Cerebral Vascular Biology: Transport and Its Regulation. Advances in Experimental Medicine and Biology, Plenum Press, New York.
9. Bodor, N. and Brewster, M. (1983) Problems of delivery of drugs to the brain. Pharmacol. Ther. 19, 337-386.
10. Bodor, N. (1987) Redox drug delivery for targeting drugs to the brain. Ann. N.Y. Acad. Sci. 507, 289-306.
11. Brewster, M.E. and Bodor, N. (1992) Redox approaches to drug delivery to the central nervous system. NIDA Monogr. Ser. 120, 169-201.
12. Fenstermacher, J.D. and Rapoport, S.I. (1984) Blood-brain barrier. In: E.M. Renkin and C.C. Michel (Eds), Handbook of Physiology. Section 2: The Cardiovascular System. Vol IV: Microcirculation, American Physiological Society, Washington, DC, pp. 969-1000.
13. Reese, T. and Karnovsky, M. (1967) Fine structural localization of a blood-brain barrier to exogenous peroxidase. J. Cell Biol. 34, 207-217.
14. Brightman, M.W. and Reese, T.S. (1969) Junctions between intimately apposed cell membranes in the vertebrate brain. J. Cell Biol. 40, 648-677.
15. Brightman, M.W. (1977) Morphology of blood-brain interfaces. Exp. Eye Res. 25 (Suppl.), 1-25.
16. Turin, L., Behe, P., Plonsky, I. and Barkovskaya, A.D. (1991) Hydrophobic ion transfer between membranes of adjacent hepatocytes: a possible probe of tight junction structure. Proc. Natl. Acad. Sci. USA 88, 9365-9369.
17. Pinto da Silva, P. and Kachar, B. (1982) On tight-junction structure. Cell 28, 441-450.
18. Kachar, B. and Reese, T.S. (1982) Evidence for the lipidic nature of tight junction strands. Nature 296, 464-466.
19. Brightman, M.W. and Tao-Cheng, J.H. (1993) Tight junctions of brain endothelium and epithelium. In: W.M. Pardridge (Ed.), The Blood-Brain Barrier: Cellular and Molecular Biology, Raven Press, New York, pp. 107-125.
20. Betz, A.L., Firth, J.A. and Goldstein, G.W. (1980) Polarity of the blood-brain barrier: distribution of enzymes between the luminal and abluminal membranes of brain capillary endothelial cells. Brain Res. 192, 17-28.
21. Brightman, M.W. (1975) Ultrastructural characteristics of adult choroid plexus: relation to the blood-cerebrospinal fluid barrier to proteins. In: M.G. Netsky and S. Shuangshoti (Eds), The Choroid Plexus in Health and Disease, University Press of Virginia, Charlottesville, pp. 86-112.
22. Bouldin, T.W. and Krigman, M.R. (1975) Differential permeability of cerebral capillary and choroid plexus to lanthanum ion. Brain Res. 99, 444-448.
23. Crone, C. (1991) The blood-brain barrier - facts and questions. In: B.K. Siesjo and S.C. Sorensen (Eds), Ion Homeostasis of the Brain (Alfred Benzon Symp. III), Munksgaard. Copenhagen, pp. 52-62.
24. Dykstra, K.H., Arya, A., Arriola, D.M., Bungay, P.M., Morrison, P.F. and Dedrick, R.L. (1993) Microdialysis study of zidovudine (AZT) transport in rat brain. J. Pharmacol. Exp. Ther. 267, 1227-1236.
25. Dykstra, K.H., Hsiao, J.K., Morrison, P.F., Bungay, P.M., Mefford, I.N., Scully, M.M. and Dedrick, R.L. (1992) Quantitative examination of tissue concentration profiles associated with microdialysis. J. Neurochem. 58, 931-940.
26. Bobo, R.H., Laske, D.W., Akbasak, A., Morrison, P.F., Dedrick, R.L. and Oldfield, E.H. (1994) Convection-enhanced delivery of macromolecules in the brain. Proc. Natl. Acad. Sci. USA 91, 2076-2080.
27. Collins, J.M. and Dedrick, R.L. (1983) Distributed model for drug delivery to CSF and brain tissue. Am. J. Physiol. 245, R303-R310.
28. Willemsen, R., Wisselaar, H.A. and van der Ploeg, A.T. (1990) Plasmalemmal vesicles are involved in transendothelial transport of albumin, lysosomal enzymes and mannose-6-phosphate receptor fragments in capillary endothelium. J. Cell Biol. 51, 235-241.
29. Simionescu, M., Ghitescu, L. and Fixman, A. (1987) How plasma macromolecules cross the endothelium. New Physiol. Sci. 2, 97-100.
30. Milici, A.J., Watrous, N.E., Stukenbok, H. and Palade, G.E. (1987) Transcytosis of albumin in capillary endothelium. J. Cell Biol. 105, 2603-2612.
31. Ghitescu, L., Fixman, A., Simionescu, M. and Simionescu, N. (1986) Specific binding sites for albumin restricted to plasmalemmal vesicles of continuous capillary endothelium: receptor-mediated transcytosis. J. Cell Biol. 102, 1304-1311.
32. Schneeberger, E.E. (1983) Proteins and vesicular transport in capillary endothelium. Fed. Proc. 42, 2419-2424.
33. Bundgaard, M. (1986) Pathways across the vertebrate blood-brain barrier: morphological viewpoints. Ann. N.Y. Acad. Sci. 484, 7-19.
34. Bundgaard, M. (1983) Vesicular transport in capillary endothelium: does it occur? Fed. Proc. 42, 2425-2430.
35. Bundgaard, M., Frokjaer-Jensen, J. and Crone, C. (1979) Endothelial plasmalemmal vesicles as elements in a system of branching invaginations from the cell surface. Proc. Natl. Acad. Sci. USA 76, 6439-6442.
36. Broadwell, R.D. and Banks, W.A. (1993) Cell biological perspective for the transcytosis of peptides and proteins through the mammalian blood-brain fluid barriers. In: W.M. Pardridge (Ed.), The Blood-Brain Barrier: Cellular and Molecular Biology, Raven Press, New York, pp. 165-199.
37. Drewes, L.R. and Betz, A.L. (1993) Frontiers in Cerebral Vascular Biology: Transport and Its Regulation, Advances in Experimental Medicine and Biology, Plenum Press, New York.
38. Gjedde, A. (1992) Blood-brain glucose transfer. In: M.W.B. Bradbury (Ed.), Physiology and Pharmacology of the Blood-Brain Barrier, Springer-Verlag, Berlin, pp. 65-115.
39. Pardridge, W.M. and Boado, R.J. (1993) Molecular cloning and regulation of gene expression of blood-brain barrier glucose transporter. In: W.M. Pardridge (Ed.), The Blood-Brain Barrier: Cellular and Molecular Biology, Raven Press, New York, pp. 395-440.
40. Pardridge, W.M., Triguero, D., Yang, J. and Cancilla, P.A. (1990) Comparison of in vitro and in vivo models of drug transcytosis through the blood-brain barrier. J. Pharmacol. Exp. Ther. 253, 884-891.
41. Farrell, C.L. and Pardridge, W.M. (1991) Blood-brain barrier glucose transporter is asymmetrically distributed on brain capillary endothelial lumenal and ablumenal membranes: an electron microscopic immunogold study. Proc. Natl. Acad. Sci. 88, 5779-5783.
42. Schielke, G.P. and Betz, A.L. (1992) Electrolyte transport. In: M.W.B. Bradbury (Ed.), Physiology and Pharmacology of the Blood-Brain Barrier, Springer-Verlag, Berlin, pp. 221-243.
43. Betz, A.L. and Goldstein, G.W. (1986) Specialized properties and solute transport in brain capillaries. Annu. Rev. Physiol. 48, 241-250.
44. Lefauconnier, J.-M. (1992) Transport of amino acids. In: M.W.B. Bradbury (Ed.), Physiology and Pharmacology of the Blood-Brain Barrier, Springer-Verlag, Berlin, pp. 117-150.
45. Segal, M.B. and Zlokovic, B.V. (1990) The Blood-Brain Barrier, Amino Acids and Peptides, Kluwer Academic Publishers, Dordrecht, The Netherlands.
46. Frey, A. (1993) Gamma-glutamyl transpeptidase: molecular cloning and structural and functional features of a blood-brain barrier marker protein. In: W.M. Pardridge (Ed.), The Blood-Brain Barrier: Cellular and Molecular Biology, Raven Press, New York, pp. 339-368.
47. Pardridge, W.M. (1983) Brain metabolism: A perspective from the blood-brain barrier. Physiol. Rev. 63, 1481-1535.
48. Begley, D.J. (1992) Peptides and the blood-brain barrier. In: M.W.B. Bradbury (Ed.), Physiology and Pharmacology of the Blood-Brain Barrier, Springer-Verlag, Berlin, pp. 151-203.
49. Pratt, O.E. (1992) The movement of vitamins into the brain. In: M.W.B. Bradbury (Ed.), Physiology and Pharmacology of the Blood-Brain Barrier, Springer-Verlag, Berlin, pp. 205-220.
50. Spector, R. and Eells, J. (1984) Deoxynucleoside and vitamin transport into the central nervous system. Fed. Proc. 43, 196-200.
51. Cordon-Cardo, C., O'Brien, J.P., Casals, D., Rittman-Grauer, L., Biedler, J.L., Melamed, M.R. and Bertino, J.R. (1989) Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites. Proc. Natl. Acad. Sci. USA 86, 695-698.
52. Jette, L. and Beliveau, R. (1993) P-Glycoprotein is strongly expressed in brain capillaries. In: L.R. Drewes and A.L. Betz (Eds), Frontiers in Cerebral Vascular Biology: Transport and Its Regulation, Plenum Press, New York, pp. 121-125.
53. Hamada, H. and Tsuruo, T. (1988) Characterization of the ATPase activity of the Mr 170,000 to 180,000 membrane glycoprotein (P-glycoprotein) associated with multidrug resistance in K562/ADM cells. Cancer Res. 48, 4926-4932.
54. Sakata, A., Tamai, I., Kawazu, K., Deguchi, Y., Ohnishi, T., Saheki, A. and Tsuji, A. (1994) In vivo evidence for ATP-dependent and P-glycoprotein-mediated transport of cyclosporin A at the blood-brain barrier. Biochem. Pharmacol. 48, 1989-1992.
55. Gomori, G. (1941) The distribution of phosphatase in normal organs and tissues. J. Cell Comp. Physiol. 17, 71-83.
56. Djuricic, B.M. and Mrsulja, B.B. (1977) Enzymic activity of the brain: microvessels vs. total forebrain homogenate. Brain Res. 138, 561-564.
57. Dallaire, L., Tremblay, L. and Beliveau, R. (1991) Purification and characterization of metabolically active capillaries of the blood-brain barrier. Biochem. J. 276, 745-752.
58. Bertler, A., Falck, B., Owman, C. and Rosengren, E. (1966) Localization of monoaminergic blood-brain barrier mechanisms. Pharmacol. Rev. 18, 369-385.
59. Hardebo, J.E., Falck, B., Owman, C. and Rosengren, E. (1979) Studies on the enzymatic blood-brain barrier: Quantitative measurements of DOPA decarboxylase in the wall of microvessels as related to the parenchyma in various CNS regions. Acta Physiol. Scand. 105, 453-460.
60. Hardebo, J.E. and Owman, C. (1979) Barrier mechanisms for neurotransmitter monoamines and their precursors at the blood-brain barrier. Ann. Neurol. 8, 1-11.
61. Hardebo, J.E. and Owman, C. (1980) Characterization of the in vitro uptake of monoamines into brain microvessels. Acta Physiol. Scand. 108, 223-229.
62. Hardebo, J.E., Emson, P.C., Falck, B., Owman, C. and Rosengren, E. (1980) Enzymes related to monoamine transmitter metabolism in brain microvessels. J. Neurochem. 35, 1388-1393.
63. Ghersi-Egea, J.-F., Minn, A. and Siest, G. (1988) A new aspect of the protective functions of the blood-brain barrier: activities of four drug-metabolizing enzymes in isolated rat brain microvessels. Life Sci. 42, 2515-2523.
64. Ghersi-Egea, J.F., Leninger-Muller, B., Suleman, G., Siest, G. and Minn, A. (1994) Localization of drug-metabolizing enzyme activities to blood-brain interfaces and circumventricular organs. J. Neurochem. 62, 1089-1096.
65. Brecher, P., Tercyak, A., Gavras, H. and Chobanian, AV. (1978) Peptidyl dipeptidase in rabbit brain microvessels. Biochim. Biophys. Acta 526, 537-546.
66. Mistry, G. and Drummond, G.I. (1986) Adenosine metabolism in microvessels from heart and brain. J. Mol. Cell Cardiol. 18, 13-22.
67. Schrader, W.P., West, C.A. and Strominger, N.L. (1987) Localization of adenosine deaminase and adenosine deaminase complexing protein in rabbit brain. J. Histochem. Cytochem. 35, 443-451.
68. Betz, A.L. (1985) Identification of hypoxanthine transport and xanthine oxidase activity in brain capillaries. J. Neurochem. 44, 574-579.
69. Stella, V. and Himmelstein, K.J. (1985) Site-specific drug delivery via prodrugs. In: H. Bundgaard (Ed.), Design of Prodrugs, Elsevier, Amsterdam, pp. 177-198.
70. Stella, V.J. and Himmelstein, K.J. (1980) Prodrugs and site-specific delivery. J. Med. Chem. 23, 1275-1282.
71. Stella, V.J. and Himmelstein, K.J. (1982) Critique of prodrugs and site specific delivery. In: H. Bundgaard, A.B. Hansen and H. Kofod (Eds), Optimization of Drug Delivery (Alfred Benzon Symposium), Munksgaard, Copenhagen, pp. 134-155.
72. Boddy, A., Aarons, L. and Petrak, K. (1989) Efficiency of drug targeting: steady-state considerations using a three-compartment model. Pharm. Res. 6, 367-372.
73. Tomlinson, E. (1987) Theory and practice of site-specific drug delivery. Adv. Drug Deliv. Rev. 1, 87-164.
74. Anderson, B.D., Galinsky, R.E., Baker, D.C., Chi, S.-C., Hoesterey, B.L., Morgan, M.E., Murakami, K. and Mitsuya, H. (1992) Approaches toward the optimization of CNS uptake of anti-AIDS agents. J. Control. Release 19, 219-230.
75. Navia, B.A., Jordan, B.D. and Price, R.W. (1986) The AIDS dementia complex: I. Clinical features. Ann. Neurol. 19, 517-524.
76. Navia, B.A., Cho, E.-S., Petito, C.K. and Price, R.W. (1986) The AIDS dementia complex: II. Neuropathology. Ann. Neurol. 19, 525-535.
77. Price, R.W. and Brew, B.J. (1988) The AIDS dementia complex. J. Infect. Dis. 158, 1079-1083.
78. Barchi, J.J., Jr, Marquez, V.E., Driscoll, J.S., Ford, H., Jr., Mitsuya, H., Shirasaka, T., Aoki, S. and Kelley, J.A. (1991) Potential anti-AIDS drugs. Lipophilic, adenosine deaminase-activated prodrugs. J. Med. Chem. 34, 1647-1655.
79. Galinsky, R.E., Flaharty, K.K., Hoesterey, B.L. and Anderson, B.D. (1991) Probenecid enhances central nervous system uptake of 2′,3′-dideoxyinosine by inhibiting cerebrospinal fluid efflux. J. Pharmacol. Exp. Ther. 257, 972-978.
80. Anderson, B.D., Hoesterey, B.L., Baker, D.C. and Galinsky, R.E. (1990) Uptake kinetics of 2′,3′-dideoxyinosine into brain and cerebrospinal fluid of rats: intravenous infusion studies. J. Pharmacol. Exp. Ther. 253, 113-118.
81. Brouwers, P. (1991) Treatment-related changes in pediatric cognitive function. Workshop on Neuro-AIDS: Drug Discovery and Development, Portland, ME.
82. Balis, F.M., Pizzo, P.A., Butler, K.M., Hawkins, M.E., Brouwers, P., Husson, R.N., Jacobsen, F., Blaney, S.M., Gress, J., Jarosinski, P. and Poplack, D.G. (1992) Clinical pharmacology of 2′,3′-dideoxyinosine in human immunodeficiency virus-infected children. J. Infect. Dis. 165, 99-104.
83. Butler, K.M., Husson, R.N., Balis, F.M., Brouwers, P., Eddy, J., El-Amin, D., Gress, J., Hawkins, M., Jarosinski, P., Moss, H., Poplack, D., Santacroce, S., Venzon, D., Wiener, L., Wolters, P. and Pizzo, P.A. (1991) Dideoxyinosine in children with symptomatic human immunodeficiency virus infection. New Engl. J. Med. 324, 137-144.
84. Morgan, M.E., Chi, S.-C., Murakami, K., Mitsuya, H. and Anderson, B.D. (1992) Central nervous system targeting of 2′,3′-dideoxyinosine via adenosine deaminase-activated 6-halo-dideoxypurine prodrugs. Antimicrob. Agents Chemother. 36, 2156-2165.
85. Murakami, K., Shirasaka, T., Yoshioka, H., Kojima, E., Aoki, S., Ford, H., Jr., Driscoll, J.S., Kelley, J.A. and Mitsuya, H. (1991) Escherichia coli mediated biosynthesis and in vitro anti-HIV activity of lipophilic 6-halo-2′,3′-dideoxypurine nucleosides. J. Med. Chem. 34, 1606-1612.
86. Shirasaka, T., Murakami, K., Ford, H., Kelly, J.A., Yoshioka, H., Kojima, E., Aoki, S., Broder, S. and Mitsuya, H. (1990) Lipophilic halogenated congeners of 2′,3′-dideoxypurine nucleosides active against human immunodeficiency virus in vitro. Proc. Natl. Acad. Sci. USA 87, 9426-9430.
87. Shirasaka, T., Watanabe, K., Yoshioka, H., Kojima, E., Aoki, S., Murakami, K. and Mitsuya, H. (1991) Lipophilic 6-halo-2′,3′-dideoxypurine nucleosides: potential antiretroviral agents targeting HIV-associated neurologic disorders. In: A. Kumar (Ed.), Advances in Molecular Biology and Targeted Treatment for AIDS, Plenum Press, New York, pp. 323-333.
88. Anderson, B.D., Hoesterey, B.L., Baker, D.C. and Galinsky, R.E. (1990) Kinetics of ddI in plasma, brain, and csf of rats after administration of ddI and an ester prodrug of ddI. Ann. N.Y. Acad Sci. 616, 472-474.
89. Wade, L.A. and Katzman, R. (1975) Synthetic amino acids and the nature of L-dopa transport at the blood-brain barrier. J. Neurochem. 25, 837-842.
90. Markovitz, D.C. and Fernstrom, J.D. (1977) Diet and uptake of Aldomet into brain: competition with natural large neutral amino acids. Science 197, 1014-1015.
91. Greig, N., Momma, S., Sweeney, D., Smith, Q. and Rapoport, S. (1987) Facilitated transport of melphalan at the rat blood-brain barrier by the large neutral amino acid carrier system. Cancer Res. 47, 1571-1576.
92. Greig, N.H., Sweeney, D.J. and Rapoport, S.I. (1988) Comparative brain and plasma pharmacokinetics and anticancer activities of chlorambucil and melphalan in the rat. Cancer Chemother. Pharmacol. 21, 1-8.
93. Cornford, E.M., Young, D., Paxton, J.W., Finlay, G.J., Wilson, W.R. and Pardridge. W.M. (1992) Melphalan penetration of the blood-brain barrier via the neutral amino acid transporter in tumor bearing brain. Cancer Res. 52, 138-143.
94. Chastain, I.E. and Borchardt, R.T. (1990) Acivicin transport across brain microvessel endothelial cell monolayers: a model of the blood-brain barrier. Neurosci. Res. Commun. 6, 51-55.
95. Williams, M.G., Earhart, R.H., Bailey, H. and McGovren, J.P. (1990) Prevention of central nervous system toxicity of the antitumor antibiotic acivicin by concomitant infusion of an amino acid mixture. Cancer Res. 50, 5475-5480.
96. Takada, Y., Greig, N.H., Vistica, D.T., Rapoport, S.I. and Smith, Q.R. (1991) Affinity of antineoplastic amino acid drugs for the large neutral amino acid transporter of the blood-brain barrier. Cancer Chemother. Pharmacol. 29, 89-94.
97. van Bree, J.B.M.M., Heijligers-Feijen, C.D., de Boer, A.G., Danhof, M. and Breimer, D.D. (1991) Stereoselective transport of baclofen across the blood-brain barrier in the rats as determined by the unit impulse response methodology. Pharm. Res. 8, 259-262.
98. van Bree, J.B.M.M., Audus, K.L. and Borchardt, R.T. (1988) Carrier-mediated transport of baclofen across monolayers of bovine brain endothelial cells in primary culture. Pharm. Res. 5, 369-371.
99. Fekete, I., Griffith, O.W., Schlageter, K.E., bigner, D.D., Friedman, H.S. and Groothuis, D.R. (1990) Rate of buthionine sulfoximine entry into brain and xenotransplanted human gliomas. Cancer Res. 50, 1251.
100. Suzuki, H., Sawada, Y., Sugiyama, Y., Iga, T. and Hanano, M. (1989) Facilitated transport of benzylpenicillin through the blood-brain barrier in rats. J. Pharmacobio-Dyn. 12, 182.
101. Spector, R. (1987) Ceftriaxone transport through the blood-brain barrier. J. Infect. Dis. 156, 209-211.
102. Matsushita, H., Suzuki, H., Sugiyama, Y., Sawada, Y., Iga, T., Kawaguchi, Y. and Hanano, M. (1991) Facilitated transport of cefodizime into the rat central nervous system. J. Pharmacol. Exp. Ther. 259, 620-625.
103. Cornford, E.M., Diep, C.P. and Pardridge, W.M. (1985) Blood-brain barrier transport of valproic acid. J. Neurochem. 44, 1541-1550.
104. Terasaki, T., Takakuwa, S., Moritani, S. and Tsuji, A. (1991) Transport of monocarboxylic acids at the blood-brain barrier: Studies with monolayers of primary cultured bovine brain capillary endothelial cells. J. Pharmacol. Exp. Ther. 258, 932-937.
105. Banks, W.A., Kastin, A.J. and Barrera, C.M. (1991) Delivering peptides to the central nervous system: Dilemmas and strategies. Pharm. Res. 8, 1345-1350.
106. Banks, W.A. and Kastin, A.J. (1987) Minireview: Saturable transport of peptides across the blood-brain barrier. Life Sci. 41, 1319-1338.
107. Begley, D.J. (1994) Peptides and the blood-brain barrier: The status of our understanding. Ann. N.Y. Acad. Sci. 739, 89-100.
108. Ermisch, A., Brust, P., Kretzschmar, R. and Ruhle, H.-J. (1993) Peptides and blood-brain barrier transport. Phys. Rev. 73, 489-527.
109. 18F]fluorodopa uptake into human brain by amino acids demonstrated by positron emission tomography. Ann. Neurol. 20, 258-262.
110. Greig, N.H., Sweeney, D.J. and Rapoport, S.I. (1987) Melphalan concentration dependent plasma protein binding in healthy humans and rats. Eur. J. Clin. Pharmacol. 32, 179-185.
111. Greig, N.H. (1989) Drug delivery to the brain by blood-brain barrier circumvention and drug modification. In: E.A. Neuwelt (Ed.), Implications of the Blood-Brain Barrier and Its Manipulation, Plenum, New York, pp. 311-367.
112. Smith, Q.R., Momma, S., Aoyagi, M. and Rapoport, S.I. (1987) Kinetics of neutral amino acid transport across the blood-brain barrier. J. Neurochem. 49, 1651-1658.
113. Takada, Y., Vistica, D.T., Greig, N.H., Purdon, D., Rapoport, S.I. and Smith, Q.R. (1992) Rapid high-affinity transport of a chemotherapeutic amino acid across the blood-brain barrier. Cancer Res. 52, 2191-2196.
114. Vistica, D.T., Ahmad, S., Fuller, R. and Hill, J. (1986) Transport and cytotoxicity of amino acid nitrogen mustards: implications for design of more selective antitumor agents. Fed. Proc. 45, 2447-2450.
115. Greig, N.H. (1992) Drug entry into the brain and its pharmacologic manipulation. In: M.W.B. Bradbury (Ed.), Physiology and Pharmacology of the Blood-Brain Barrier, Springer-Verlag, Berlin, pp. 487-523.
116. Walker, I., Nicholls, D., Irwin, W.J. and Freeman, S. (1994) Drug delivery via active transport at the blood-brain barrier: Affinity of a prodrug of phosphonoformate for the large amino acid transporter. Int. J. Pharm. 104, 157-167.
117. Warren, S. and Williams, M.R. (1971) The acid-catalysed decarboxylation of phosphonoformic acid. J. Chem. Soc. B 618-621.
118. Mitchell, A.G., Nicholls, D., Walker, I., Irwin, W.J. and Freeman, S. (1991) Prodrugs of phosphonoformate: Products, kinetics and mechanisms of hydrolysis of dibenzyl (methoxycarbonyl)phosphonate. J. Chem. Soc. Perkin Trans. 2, 1297-1303.
119. Mitchell, A.G., Nicholls, D., Irwin, W.J. and Freeman, S. (1992) Prodrugs of phosphonoformate: The effect of para-substituents on the products, kinetics and mechanism of hydrolysis of dibenzyl (methoxycarbonyl)phosphonate. J. Chem. Soc. Perkin Trans. 2, 1145-1151.
120. Krol, E.S. and Thatcher, G.R.J. (1993) Hydrolysis of phosphonoformate triesters: Rate acceleration of a millionfold in nucleophilic substitution at phosphorus. J. Chem. Perkin Trans. 2, 793-794.
121. Krol, E.S., Davis, J.M. and Thatcher, G.R.J. (1991) Hydrolysis of phosphonoformate esters: Product distribution and reactivity patterns. J. Chem. Soc. Chem. Commun. 118-119.
122. Walker, I., Nicholls. D., Irwin, W.J. and Freeman, S. (1994) Drug delivery via active transport at the blood-brain barrier: II. Investigation of monocarboxylic acid transport in vitro. Int. J. Pharm. 108, 225-232.
123. Henin, Y., Gouyette, C., Schwartz, O., Debouzy, J.-C., Neumann, J.-M. and Huynh-Dinh, T. (1991) Lipophilic glycosyl phosphotriester derivatives of AZT: synthesis, NMR transmembrane transport study, and antiviral activity. J. Med. Chem. 34, 1830-1837.
124. Namane, A., Gouyette, C., Fillion, M.-P., Fillion, G. and Huynh-Dinh, T. (1992) Improved brain delivery of AZT using a glycosyl phosphotriester prodrug. J. Med. Chem. 35, 3039-3044.
125. Durrer, A., Walther, B., Racciatti, A., Boss, G. and Testa, B. (1991) Structure-metabolism relationships in the hydrolysis of nicotinate esters by rat liver and brain subcellular fractions. Pharm. Res. 8, 832-839.
126. Ghosh, M.K. and Mitra, A.K. (1992) Enhanced delivery of 5-iodo-2′-deoxyuridine to the brain parenchyma. Pharm. Res. 9, 1173-1176.
127. Ghosh, M.K. and Mitra, A.K. (1992) Brain parenchymal metabolism of 5-iodo-2′-deoxyuridine and 5′-ester prodrugs. Pharm. Res. 9, 1048-1052.
128. Hoesterey, B.L., Galinsky, R.E. and Anderson, B.D. (1991) Dose dependence in the plasma pharmacokinetics and uptake kinetics of 2′,3′-dideoxyinosine (ddI) into brain and csf of rats. Drug Metab. Dispos. 19, 907-912.
129. Wong, S.L., Hedaya, M.A. and Sawchuk, R.J. (1992) Competitive inhibition of zidovudine clearance by probenecid during continuous coadministration. Pharm. Res. 9, 228-235.
130. Galinsky, R.E., Hoesterey, B.L. and Anderson, B.D. (1990) Brain and cerebrospinal fluid uptake of zidovudine (AZT) in rats after intravenous injection. Life Sci. 47, 781-788.
131. Tuntland, T., Ravasco, R.J., Al-Habet, S. and Unadkat, J.D. (1993) Active efflux of zidovudine and 2′,3′-di-deoxyinosine out of the cerebrospinal fluid when administered alone and in combination to the Macaca nemestrina. Pharm. Res. 11, 312-317.
132. Hedaya, M.A. and Sawchuk, R.J. (1989) Effect of probenecid on the renal and nonrenal clearances of zidovudine and its distribution into cerebrospinal fluid in the rabbit. J. Pharm, Sci. 78, 716-722.
133. Wang, Y. and Sawchuk, R.J. (1995) Zidovudine transport in the rabbit brain during intravenous and intracerebroventricular infusion. J. Pharm. Sci. 84, 871-876.
134. Tsuzuki, N., Hama, T., Kawada, M., Hasui, A., Konishi, R., Shiwa, S., Ochi, Y., Futaki, S. and Kitagawa, K. (1994) Adamantane as a brain-directed drug carrier for poorly absorbed drug. 2. AZT derivatives conjugated with the 1-adamantane moiety. J. Pharm. Sci. 83, 481-484.
135. Robinson, P.J. and Rapoport, S.I. (1986) Kinetics of protein binding determine rates of uptake of drugs by brain. Am. J. Physiol. 351, R1212-R1220.
136. Robinson, P.J. and Rapoport, S.I. (1992) Transport of drugs. In: M.W.B. Bradbury (Ed.), Physiology and Pharmacology of the Blood-Brain Barrier, Springer-Verlag, Berlin, pp. 279-300.
137. Raub, T.J., Barsuhn, C.L., Williams, L.R., Decker, D.E., Sawada, G.A. and Ho, N.F.H. (1993) Use of a biophysical-kinetic model to understand the roles of protein binding and membrane partitioning on passive diffusion of highly lipophilic molecules across cellular barriers. J. Drug Target. 1, 269-286.
138. Greig, N.H., Soncrant, T.T., Shetty, H.U., Momma, S. and Smith, Q.R. (1990) Brain uptakes and anticancer activities of vincristine and vinblastine are restricted by their low cerebrovascular permeability and binding to plasma constituents in rat. Cancer Chemother. Pharmacol. 26, 263-268.
139. Greig, N.H., Genka, S., Daly, E.M., Sweeney, D.J. and Rapoport, S.I. (1990) Physicochemical and pharmacokinetic parameters of seven lipophilic chlorambucil esters designed for brain penetration. Cancer Chemother. Pharmacol. 25, 311-319.
140. Rosowsky, A., Abelson, H., Beardsley, G., Ensminger, W.D., Kufe. D.W., Steele, G. and Modest, E.J. (1982) Pharmacological studies on the dibutyl and γ-monobutyl esters of methotrexate in the rhesus monkey. Cancer Chemother. Pharmacol. 10, 55-61.
141. Greig, N.H., Daly, E.M., Sweeney, D.J. and Rapoport, S.I. (1990) Pharmacokinetics of chlorambucil-tertiary butyl ester, a lipophilic chlorambucil derivative that achieves and maintains high concentrations in brain. Cancer Chemother. Pharmacol. 25, 311-319.
142. Tower, D.B. (1960) Administration of GABA to man: Systemic effect and anticonvulsant action. In: E. Roberts (Ed.), Inhibition in the Nervous System and GABA, Pergamon Press, New York, pp. 562-578.
143. Hayashi, T. (1959) The inhibitory action of β-hydroxy-γ-aminobutyric acid upon the seizure following stimulation of the motor cortex of the dog. J. Physiol. (Lond.) 145, 570-578.
144. Jacob, J.N., Shashoua, V.E., Campbell, A. and Baldessarini, R.J. (1985) γ-Aminobutyric acid esters. 2. Synthesis, brain uptake, and pharmacological properties of lipid esters of γ-aminobutyric acid. J. Med. Chem. 28, 106-110.
145. Jacob, J.N., Hesse, G.W. and Shashoua, V.E. (1990) Synthesis, brain uptake, and pharmacological properties of a glyceryl lipid containing GABA and the GABA-T inhibitor γ-vinyl-GABA. J. Med. Chem. 33, 733-736.
146. Shashoua, V.E., Jacob, J.N., Ridge, R., Campbell, A. and Baldessarini, R.J. (1984) γ-Aminobutyric acid esters. 1. Synthesis, brain uptake, and pharmacological studies of aliphatic and steroid esters of γ-aminobutyric acid. J. Med. Chem. 27, 659-664.
147. Hesse, G.W., Jacob, J.N. and Shashoua, V.E. (1988) Uptake in brain and neurophysiological activity of two lipid esters of γ-aminobutyric acid. Neuropharmacology 27, 637-640.
148. Hesse, G.W., Shashoua, V.E. and Jacob, J.N. (1985) Inhibitory effect of cholesteryl γ-aminobutyrate on evoked activity in rat hippocampal slices. Neuropharmacology 24, 139-146.
149. Mergen, F., Lambert, D.M., Goncalves Saraiva, J.C., Poupaert, J.H. and Dumont, P. (1991) Antiepileptic activity of 1,3-dihexadecanoylamino-2-valproyl-propan-2-ol, a prodrug of valproic acid endowed with a tropism for the central nervous system. J. Pharm. Pharmacol. 43, 815-816.
150. Frey, H.H. and Loscher, W. (1978) Distribution of valproate across the interface between blood and cerebrospinal fluid. Neuropharmacology 17, 637-642.
151. Levy, H.R. and Lai, A.A. (1982) Valproate absorption, distribution and excretion. In: D.M. Woodbury, J.K. Penry and C.E. Pippenger (Eds), Antiepileptic Drugs, Raven Press, New York, pp. 555-563.
152. Dreifuss, F.E. (1989) Valproate toxicity. In: R.H. Levy, F.E. Dreifuss, R.H. Mattson, B.S. Meldrum and J.K. Penry (Eds), Antiepileptic Drugs, 3rd Edn, Raven Press, New York, pp. 643-651.
153. Loscher, W. and Nau, H. (1985) Pharmacological evaluation of various metabolites and derivatives of valproic acid. Neuropharmacology 24, 427-435.
154. Badir, K., Haj-Yehia, A., Vree, T.B., van der Kleijn, E. and Bialer, M. (1991) Pharmacokinetics and anticonvulsant activity of three monoesteric prodrugs of valproic acid. Pharm. Res. 8, 750-753.
155. Salim, H., Badir, K., Haj Yehia, A. and Bialer, M. (1990) Pharmacokinetic analysis of esteric prodrugs of valproic acid. Pharm. Res. 7, S222.
156. Goncalves Saraiva, J.C. (1990) Propharmacomolecules sous forme de triacylglycerols: synthese et evaluation des proprietes vectrices. Ph.D. Thesis, Catholic University of Louvain, Brussels, Belgium.
157. Hersh, L.B., Aboukhair, N. and Watson, S. (1987) Immunohistochemical localization of aminopeptidase M in rat brain and periphery: Relationship of enzyme localization and enkephalin metabolism. Peptides 8, 523-532.
158. Solhonne, B., Gros, C., Pollard, H. and Schwartz, J.C. (1987) Major localization of aminopeptidase M in rat brain microvessels. Neuroscience 22, 225-232.
159. Turner, A.J., Hooper, N.M. and Kenny, A.J. (1987) Metabolism of neuropeptides. In: A.J. Kenny and A.J. Turner (Eds), Mammalian Ectoenzymes, Elsevier, Amsterdam, pp. 221-241.
160. Malfroy, B., Swerts, J.P., Guyon, A., Roques, B.P. and Schwartz, J.-C. (1978) High affinity enkephalin-degrading peptidase in brain is increased after morphine. Nature 276, 523-526.
161. Guyon, A., Roques, B.P., Guyon, F., Foucault, A., Perdrisot, R., Swerts, J.P. and Schwartz, J.C. (1979) Enkephalin degradation in mouse brain studied by a new HPLC method: further evidence for the involvement of a carboxydipeptidase. Life Sci. 25, 1605-1612.
162. Hersh, L.B. (1985) Characterization of the membrane-bound aminopeptidase from rat brain: identification of the enkephalin degrading aminopeptidase. J. Neurochem. 44, 1427-1435.
163. Waksman, G., Bouboutou, R., Devin, J., Bourgoin, S., Cesselin, F., Hamon, M., Fournie-Zaluski, M.-C. and Roques, B.P. (1985) In vitro and in vivo effects of kelatorphan on enkephalin metabolism in rodent brain. Eur. J. Pharmacol. 117, 233-243.
164. Hambrook, J.M., Morgan, B.A., Rance, M.J. and Smith, C.F. (1976) Mode of deactivation of the enkephalins by rat and human plasma and rat brain homogenates. Nature 262, 782-782.
165. 5)enkephalin in brain slices using peptidase inhibitors and anti-amino-peptidase N antibodies. Mol. Pharmacol. 29, 281-287.
166. Roques, B.P. and Fournie-Zaluski, M. (1986) Enkephalin degrading enzyme inhibitors: a physiological way to new analgesics and psychoactive agents. NIDA Monogr. Ser. 70, 128-154.
167. Chipkin, R.E. (1986) Inhibitors of enkephalinase: the next generation of analgesics. Drugs Future 11, 593-607.
168. Barnard, E.A., Borsodi, A., Goodman, M., Hill, R., Hunter, J.C., Moroder, L., Pasternak, G.W., Portoghese, P.S., Przewlocki, R. and Roques, B.P. (1991) What is the molecular basis of opioid antinociception and how does this information point to new drug design? In: A. Basbaum and J.M. Besson (Eds), Towards a New Pharmacotherapy of Pain, John Wiley and Sons Ltd., New York, pp. 299-315.
169. Roques, B.P., Lucas-Soroca, E., Chaillet, P., Costentin, J. and Fournie-Zaluski, M.C. (1980) The enkephalinase inhibitor thiorphan shows antinociceptive activity in mice. Nature 288, 286-288.
170. Lecomte, J.M., Costentin, J., Vlaiculescu, A., Chaillet, P., Marcais-Collado, H., Llorens-Cortes, C., Leboyer, M. and Schwartz, J.-C. (1986) Pharmacological properties of acetorphan, a parenterally active 'enkephalinase' inhibitor. J. Pharmacol. Exp. Ther. 237, 937-944.
171. Lambert, S.M., Mergen, F., Poupaert, J.H. and Dumont, P. (1993) Analgesic potency of S-acetylthiorphan after intravenous administration to mice. Eur. J. Pharmacol. 243, 129-134.
172. Fournie-Zaluski, M.-C., Coric, P., Turcaud, S., Lucas, E., Noble, F., Maldonado, R. and Roques, B.P. (1992) 'Mixed inhibitor-prodrug' as a new approach toward systemically active inhibitors of enkephalin-degrading enzymes. J. Med. Chem. 35, 2473-2481.
173. Lambert, D.M., Mergen, F., Berens, C.F., Poupaert, J.H. and Dumont, P.
174. Noble, F., Soleilhac, J.M., Soroca-Lucas, E., Turcaud, S., Fournie-Zaluski, M.C. and Roques, B.P. (1992) Inhibition of the enkephalin-metabolizing enzymes by the first systemically active mixed inhibitor prodrug RB 101 induces potent analgesic responses in mice and rats. J. Pharmacol. Exp. Ther. 261, 181-190.
175. Fournie-Zaluski, M.-C., Coric, P., Turcaud, S., Bruetschy, L., Lucas, E., Noble, F. and Roques, B.P. (1992) Potent and systemically active aminopeptidase N inhibitors designed from active-site investigation. J. Med. Chem. 35, 1259-1266.
176. Ranadive, S.A., Chen, A.X. and Serajuddin, A.T.M. (1992) Relative lipophilicities and structural-pharmacological considerations of various angiotensin-converting enzyme (ACE) inhibitors. Pharm. Res. 9, 1480-1486.
177. Gohlke, P., Urbach, H., Scholkens, B. and Unger, T. (1989) Inhibition of converting enzyme in the cerebrospinal fluid of rats after oral treatment with converting enzyme inhibitors. J. Pharmacol. Exp. Ther. 249, 609-616.
178. Nordstrom, M., Abrahamsson, T., Ervik, M., Forshult, E. and Regardh, C.G. (1993) Central nervous and systemic kinetics of ramipril and ramiprilat in the conscious dog. J. Pharmacol. Exp. Ther. 266, 147-152.
179. Kimura, T., Koike, T., Onogawa, M., Kurosaki, Y., Nakayama, T., Konishi, R., Mizobuchi, N. and Kitagawa, K. (1993) Improvement of peptide delivery to brain by chemical modification: [D-Ala2] Leu-enkephalin conjugated with 1-adamantane. Drug Deliv. Syst. 8, 181-91.
180. 2]Leu-enkephalin derivatives conjugated with the 1-adamantane moiety. Biochem. Pharmacol. 41, R5-R8.
181. Bundgaard, H. and Moss, J. (1990) Prodrugs of peptides. 6. Bioreversible derivatives of thyrotropin-releasing hormone (TRH) with increased lipophilicity and resistance to cleavage by the TRH-specific serum enzyme. Pharm. Res. 7, 885-892.
182. Frey, H.H., Popp, C. and Loscher, W. (1979) Influence of inhibitors of the high affinity GABA uptake on seizure thresholds in mice, Neuropharmacology 18, 581-590.
183. Lodge, D., Johansen, G.A.R., Curtis, D.R. and Brand, S.. (1977) Effects of areca nut constituents arecaidine and guvacine on the action of GABA in the cat central nervous system. Brain Res. 136, 513-522.
184. Hinko, C.N., Seibert, K. and Crider, A.M. (1984) Anticonvulsant activity of the nipecotic acid ester, (±)-m-nitrophenyl-3-piperidine carboxylate. Neuropharmacology 23, 1009-1014.
185. Hinko, C.N., Crider, A.M. and Wood, J.D. (1988) A comparison of prodrug esters of nipecotic acid. Neuropharmacology 27, 475-483.
186. Crider, A.M., Wood, J.D., Tschappat, K.D., Hinko, C.N. and Seibert, K. (1984) γ-Aminobutyric acid uptake inhibition and anticonvulsant activity of nipecotic acid esters. J. Pharm. Sci. 73, 1612-1616.
187. Crider, A.M., Tita, J.D., Wood, J.D. and Hinko, C.N. (1982) Esters of nipecotic acid and iso-nipecotic acid as potential anticonvulsants J. Pharm. Sci. 71, 1214-1219.
188. Altomar, C., Carotti, A., Cellamare, S., Ferappi, M., Cagiano, R. and Renna, G. (1988) QSAR analysis of chemical and serum-catalyzed hydrolysis of phenyl ester prodrugs of nipecotic acid. Int. J. Pharm. 48, 91-102.
189. Shek, E. (1994) Chemical delivery systems and prodrugs of anticonvulsive drugs. Adv. Drug Deliv. Rev. 14, 227-241.
190. Nassereddine-Sebaei, M., Crider, A.M., Carroll, R.T. and Hinko, C.N. (1993) Determination of m-nitrophenol and nipecotic acid in mouse tissues by high-performance liquid chromatography after administration of the anticonvulsant m-nitrophenyl-3-piperidinecarboxylate hydrochloride. J. Pharm. Sci. 82, 39-43.
191. Callery, P.S., Stogniew, M. and Geelhaar, L.A. (1979) Detection of the in vivo conversion of 2-pyrrolidinone to γ-aminobutyric acid in mouse brain. Biomed. Mass Spectrom. 6, 23-26.
192. Callery, P.S., Geelhaar, L.A. and Stogniew, M. (1978) 2-Pyrrolidinone - a cyclization product of γ-aminobutyric acid detected in mouse brain. Biochem. Pharmacol. 27, 2061-2063.
193. Sasaki, H., Mori, Y., Nakamura, J. and Shibasaki, J. Synthesis and anticonvulsant activity of 1-acyl-2-pyrrolidinone derivatives. J. Med. Chem. 34, 628-633.
194. Hadad, S. and Bialer, M. (1995) Pharmacokinetic analysis and antiepileptic activity of N-valproyl derivatives of GABA and glycine. Pharm. Res. 12, 905-910.
195. Wood, J.D., Krogsgaard-Larsen, P. and Schousboe, A. (1988) Amplification by glycine of the effect of the GABA transport inhibitor THPO on synaptosomal GABA level. Neurochem. Res. 13, 917-921.
196. Toth, E. and Lajtha, A. (1984) Glycine potentiates the action of some anticonvulsant drugs in some seizure models. Neurochem. Res. 8, 1711-1718.
197. Seiler, N. and Sarhan, S. (1984) Synergistic anticonvulsant effects of a GABA agonist and glycine. Gen. Pharmacol. 15, 367-369.
198. Pisani, F., Fazio, A., Oteri, G. and Di Perri, R. (1981) Dipropylacetic acid plasma levels; diurnal fluctuation during chronic treatment with dipropylacetamide. Ther. Drug Monit. 3, 297-301.
199. Billig, H., Ziv, E., Bar-On, H. and Bialer, M. (1990) The disposition of valpromide in rats and the isolated perfused rat liver. Drug. Metab. Dispos. 18, 238-244.
200. Snead III, O.C. (1991) The γ-hydroxybutyrate model of absence seizures: Correlation of regional brain levels of γ-hydroxybutyric acid and γ-butyrolactone with spike wave discharges. Neuropharmacology 30, 161-167.
201. Krisch, K. (1971) Carboxylic ester hydrolases. In: P. Boyer (Ed.), The Enzymes, Vol. 5, Academic Press, London, pp. 43-69.
202. Dixon, M. and Webb, E. (1979) Enzymes, Academic Press, New York.
203. Cooper, D.R., Marrel, C., Van de Waterbeemd, H., Testa, B., Jenner, P. and Marsden, C.D. (1987) L-Dopa esters as potential prodrugs: behavioural activity in experimental models of Parkinson's disease. J. Pharm. Pharmacol. 39, 627-635.
204. Cooper, D.R., Marrel, C., Van de Waterbeemd, H., Testa, B., Jenner, P. and Marsden, C.D. (1987) L-Dopa esters as potential prodrugs: effect on brain concentration of dopamine metabolites in reserpinized mice. J. Pharm. Pharmacol. 39, 809-818.
205. Bundgaard, H. (1989) The double prodrug concept and its applications. Adv. Drug Deliv. Rev. 3, 39-66.
206. Atack, J.R., Prior, A.M., Fletcher, S.R., Quirk, K., McKernan, R. and Ragan, C.I. (1994) Effects of L-690,488, a prodrug of the bisphosphonate inositol monophosphatase inhibitor L-690,300, on phosphatidylinositol cycle markers. J. Pharmacol. Exp. Ther. 270, 70-76.
207. Atack, J.R., Cook, S.M., Watt, A.P., Fletcher, S.r. and Ragan. C.I. (1993) In vitro and in vivo inhibition of inositol monophosphatase by the bisphosphonate L-690,330. J. Neurochem. 60, 652-658.
208. Zielke, C.L. and Suelter, C.H. (1971) Purine, Purine Nucleoside, and Purine Nucleotide Aminohydrolases. In: P. Boyer (Ed.), The Enzymes, Vol. 4, Academic Press, London, pp. 47-78.
209. Van der Weyden, M.B. and Kelley, W.N. (1976) Human adenosine deaminase. Distribution and properties. J. Biol. Chem. 251, 5448-5456.
210. Brady, T.G. and O'Donovan, C.I. (1965) A study of the tissue distribution of adenosine deaminase in six mammal species. Comp. Biochem. Physiol. 14, 101-120.
211. Ho, D.H.W., Pincus, C., Carter, C.J., Benjamin, R.S., Freireich, E.J. and Bodey, S.G.P. (1980) Distribution and inhibition of adenosine deaminase in tissues of man, rat, and mouse. Cancer Treat. Rep. 64, 629-633.
212. Ribera, E., Martinez-Vazquez, J.M., Ocana, I., Segura, R.M. and Pascual, C. (1987) Activity of adenosine deaminase in cerebrospinal fluid for the diagnosis and follow-up of tuberculous meningitis in adults. J. Infect. Dis. 155, 603-607.
213. Malan, C., Donald, P.R., Golden, M. and Taljaard, J.J.F. (1984) Adenosine deaminase levels in cerebrospinal fluid in the diagnosis of tuberculous meningitis. J. Trop. Med. Hyg. 87, 33-40.
214. da Cunha, J.G.S., Pereira, E., Melico-Silvestre, A., Gaspar, E., Azevedo-Bernarda, R. and da Costa, R.C. (1990) Prognostic significance of cerebrospinal fluid adenosine deaminase in acute bacterial meningitis. Infection 18, 125.
215. Raiteri, R., Marietta, G., Sclofaro, C. and Sinicco, A. (1989) Adenosine deaminase and HIV infection. Med. Sci. Res. 17, 187-188.
216. Atwood, W.J., Berger, J.R., Kaderman, R., Tornatore, C.S. and Major, E.O. (1993) Human immunodeficiency virus type 1 infection of the brain. Clin. Microbiol. Rev. 6, 339-366.
217. Levy, R.M. and Bredesen, D.E. (1988) Central nervous system dysfunction in acquired immunodeficiency syndrome. In: M.L. Rosemblum, R.M. Levy and D.E. Bredesens (Eds), AIDS and the Nervous System, Raven Press, New York, pp. 29-63.
218. Price, R.W., Brew, B.J., Sidtis, J., Rosenblum, M., Scheck, A.C. and Cleary, P. (1988) The brain and AIDS: Central nervous system HIV-1 infection and AIDS dementia complex. Science 239, 586-592.
219. Geleziunas, R., Schipper, H.M. and Wainberg, M.A. (1992) Pathogenesis and therapy of HIV-1 infection of the central nervous system. AIDS 6, 1411-1426.
220. Chassy, B.M. and Suhadolnik, R.J. (1967) Adenosine aminohydrolase. Binding and hydrolysis of 2- and 6-substituted purine ribonucleosides and 9-substituted adenine nucleosides. J. Biol. Chem. 242, 3655-3658.
221. Ahluwalia, G., Cooney, D.A., Mitsuya, H., Fridland, A., Flora, K.P., Hao, Z., Dalal, M., Broder, S. and Johns, D.G. (1987) Initial studies on the cellular pharmacology of 2′,3′-dideoxyinosine, an inhibitor of HIV infectivity. Biochem. Pharmacol. 36, 3797-3800.
222. Burns, C.L., Clair, M.H.S., Frick, L.W., Spector, T., Averett, D.R., English, M.L., Holmes, T.J., Krenitsky, T.A. and Koszalka, G.W. (1993) Novel 6-alkoxypurine 2′,3′-dideoxynucleosides as inhibitors of the cytopathic effect of the human immunodeficiency virus. J. Med. Chem. 36, 378-384.
223. Ford, H., Jr., Siddiqui, M.A., Driscoll, J.S., Marquez, V.E., Kelley, J.A., Mitsuya, H. and Shirasaka, T. (1995) Lipophilic, acid-stable, adenosine deaminase-activated anti-HIV prodrugs for central nervous system delivery. 2. 6-halo and 6-alkoxy prodrugs of 2′-β-fluoro-2′,3′-dideoxyinosine. J. Med. Chem. 38, 1189-1195.
224. Marquez, V.E., Tseng, C.K.-H., Mitsuya, H., Aoki, S., Kelley, J.A., Ford, J.H., Roth, J.S., Broder, S., Johns, D.G. and Driscoll, J.S. (1990) Acid-stable 2′-fluoro purine dideoxynucleosides as active agents against HIV J. Med. Chem. 33, 978-985.
225. Marquez, V.E., Tseng, C.K.-H., Kelley, J.A., Mitsuya, H., Broder, S., Roth, J.S. and Driscoll, J.S. (1987) 2′,3′-dideoxy-2′-fluoro-ara-A. An acid-stable purine nucleoside active against human immunodeficiency virus (HIV). Biochem. Pharmacol. 36, 2719-2722.
226. Wen, Y.-D., Remmel, R.P., Pham, P.T., Vince, R. and Zimmerman, C.L. (1995) Comparative brain exposure to (-)-carbovir after (-)-carbovir or (-)-6-aminocarbovir intravenous infusion in rats. Pharm. Res. 12, 911-915.
227. Anderson, B.D., Morgan, M.E. and Singhal, D. (1995) Enhanced oral bioavailability of ddI after administration of 6-Cl-ddP, an adenosine deaminase-activated prodrug, to chronically catheterized rats. Pharm. Res. 12, 1126-1133.
228. Hao, Z., Cooney, D.A., Hartman, N.R., Perno, C.F., Fridland, A., DeVico, A.L., Sarngadharan, M.G., Broder, S. and Johns, D.G. (1988) Factors determining the activity of 2′,3′-dideoxynucleosides in suppressing human immunodeficiency virus in vitro. Mol. Pharmacol. 34, 431-35.
229. Hao, Z., Cooney, D.A., Farquhar, D., Perno, C.F., Zhang, K., Masood, R., Wilson, Y., Hartman, N.R., Balzarini, J. and Johns, D.G. (1990) Potent DNA chain termination activity and selective inhibition of human immunodeficiency virus reverse transcriptase by 2′,3′-dideoxyuridine-5′-triphosphate. Mol. Pharmacol. 37, 157-163.
230. Balzarini, J., Herdewijn, P. and De Clercq, E. (1989) Differential patterns of intracellular metabolism of 2′3′-didehydro-2′,3′-dideoxythymidine and 3′-azido-2′,3′-dideoxythymidine, two potent anti-human immunodeficiency virus compounds. J. Biol. Chem. 264, 6127-6133.
231. Furman, P.A., Fyfe, J.A., Clair, M.H.S., Weinhold, K., Rideout, J.L., Freeman, G.A., Nusinoff Lehrman, S., Bolognesi, D.P., Broder, S., Mitsuya, H. and Barry, D.W. (1986) Phosphorylation of 3′-azido-3′-deoyxthymidine and selective interaction of the 5′-triphosphate with human immunodeficiency virus reverse transcriptase. Proc. Natl. Acad. Sci. USA 83, 8333-8337.
232. Balzarini, J., Cooney, D.A., Dalal, M., Kang, G.-J., Cupp, J.E., De Clercq, E., Broder, S. and Johns, D.G. (1987) 2′,3′-Dideoxycytidine: regulation of its metabolism and anti-retroviral potency by natural pyrimidine nucleosides and by inhibitors of pyrimidine nucleotide synthesis. Mol. Pharmacol. 32, 789-806.
233. Starnes, M.C. and Cheng, Y.-C. (1987) Cellular metabolism of 2′,3′-dideoxycytidine, a compound active against human immunodeficiency virus in vitro. J. Biol. Chem. 262, 988-991.
234. Johnson, M.A., Ahluwalia, G., Connelly, M.C., Cooney, D.A., Broder, S., Johns, D.G. and Fridland, A. (1988) Metabolic pathways for the activation of the antiretroviral agent 2′,3′-dideoxyadenosine in human lymphoid cells. J. Biol. Chem. 263, 15354-15357.
235. . Johnson, M. and Fridland, A. (1989) Phosphorylation of 2′,3′-dideoxyinosine by cytosolic 5′-nucleotidase of human lymphoid cells. Mol. Pharmacol. 36, 291-295.
236. Perno, C.F., Yarchoan, R., Cooney, D.A., Hartman, N.R., Webb, D.S.A., Hao, Z., Mitsuya, H., Johns, D.G. and Broder, S. (1989) Replication of human immunodeficiency virus in monocytes. J. Exp. Med. 169, 933-951.
237. Tarusova, N.B., Khorlin, A.A., Kraeveskii, A.A., Korneeva, M.N., Nosik, D.N., Kruglov, I.V., Galegov, G.A. and Bibilashvili, R.S. (1989) Inhibition of HIV reproduction in cell cultures by 5′-phosphonates of 3′- azido-2′,3′-dideoxynucleosides. Mol. Biol. (Moscow) 23, 1716-1724.
238. Mullah, K.B., Rao, T.S., Balzarini, J., De Clercq, E. and Bentrude, W.G. (1992) Potential prodrug derivatives of 2′,3′-didehydro-2′,3′-dideoxynucleosides. Preparations and antiviral activities. J. Med. Chem. 35, 2728-2735.
239. McGuigan, C., O'Connor, T.J., Nicholls, S.R., Nickson, C. and Kinchington, D. (1990) Synthesis and anti-HIV activity of some novel substituted dialkyl phosphate derivatives of AZT and dd Cyd. Antiviral Chem. Chemother. 1, 355-360.
240. McGuigan, C., Nickson, C., Petrik, J. and Karpas, A. (1992) Phosphate derivatives of AZT display enhanced selectivity of action against HIV1 by comparison to the parent nucleoside. FEBS Lett. 310, 171-174.
241. McGuigan, C., Pathirana, R.N., Balzarini, J. and De Clercq, E. (1993) Intracellular delivery of bioactive AZT nucleotides by aryl phosphate derivatives of AZT. J. Med. Chem. 36, 1048-1052.
242. Steim, J.M., Neto, C.C., Sarin, P.S., Sun, D.K., Sehgal, R.K. and Turcotte, J.G. (1990) Lipid conjugates of antiviral agents I. Azidothymidine-monophosphate-diglyeride: anti-HIV activity, physical properties, and interaction with plasma proteins. Biochem. Biophys. Res. Commun. 171, 451-457.
243. Piantadosi, C., Marasco, C.J., Jr., Morris-Natschke, S.L., Meyer, K.L., Gumus, F., Surles, J.R., Ishaq, K.S., Kucera, L.S., Iyer, N., Wallen, C.A., Piantadosi, S. and Modest, E.J. (1991) Synthesis and evaluation of novel ether lipid nucleoside conjugates for anti-HIV-1 activity. J. Med. Chem. 34, 1408-1414.
244. Hong, C.I., West, C.R., Bernacki. R.J. and Chu, C.K. (1994) Nucleoside-ether lipid conjugates as biotransformed prodrugs of antitumor and antiviral nucleosides. J. Lipid Mediators Cell Signalling 10, 159-161.
245. McGuigan, C., Nicholls, S.R., O'Connor, T.J. and Kinchington, D. (1990) Synthesis of some novel dialkyl phosphate derivatives of 3′-modified nucleosides as potential anti-AIDS drugs. Antiviral Chem. Chemother. 1, 25-33.
246. Fillion, G., Dupraz, B., Prudhomme, N. and Huynh-Dinh, T. (1994) Blood-brain penetration of 5-hydroxytryptamine derivatives. Biorg. Med. Chem. Lett. 4, 1485-1490.
247. Betz, A.L. (1993) Oxygen free radicals and the brain microvasculature. In: W.M. Pardridge (Ed.), The Blood-Brain Barrier, Raven Press, New York, pp. 303-321.
248. Terada, L.S., Willingham, I.R., Rosandich, M.E., Leff, J.A., Kindt, G.W. and Repine, J.E. (1991) Generation of superoxide anion by brain endotheliat cell xanthine oxidase. J. Cell. Physiol. 148, 191-196.
249. Bray, R.C. (1975) Molybdenum iron-sulfur flavin hydrolases and related enzymes. In: P.O. Boyer, H. Lardy and K. Myrbacks (Eds), The Enzymes, 2nd Edn, Academic Press, New York, pp. 533-556.
250. Lindsay, S., Liu, T.H., Xu, J.A., Marshall, P.A., Thompson, J.K., Parks, D.A., Freeman, B.A., Hsu, C.Y. and Beckman, J.S. (1991) Role of xanthine dehydrogenase and oxidase in focal cerebral ischemic injury to rat. Am. J. Physiol. 261, H2051-H2057.
251. Al-Khalidi, U.A.S. and Chaglassian, T.H. (1965) The species distribution of xanthine oxidase. Biochem. J. 97, 318-320.
252. Jones, D.B., Rustgi, V.K., Kornhauser, D.M., Woods, A., Quinn, R., Hoofnagle, J.H. and Jones, E.A. (1987) The disposition of 6-deoxyacyclovir, a xanthine oxidase-activated prodrug of acyclovir, in the isolated perfused rat liver. Hepatology 7, 345-348.
253. Krenitsky, T.A., Hall, W.W., De Miranda, P., Beauchamp, L.M., Schaeffer, H.J. and Whiteman, P.D. (1984) 6-Deoxyacyclovir: A xanthine oxidase-activated prodrug of acyclovir. Proc. Natl. Acad. Sci. USA 81, 3209-3213.
254. Shanmuganathan, K., Koudriakova, T., Nampalli, S., Du, J., Gallo, J.M., Schinazi, R.F. and Chu, C.K. (1994) Enhanced brain delivery of an anti-HIV nucleoside 2′-F-ara-ddI by xanthine oxidase mediated biotransformation. J. Med. Chem. 37, 821-827.
255. Finberg, J.P.M. and Youdim. M.B.H. (1983) Monoamine oxidases. In: A. Lajtha (Ed.), Handbook of Neurochemistry, 2nd Edn. Plenum Press, New York, pp. 293-313.
256. Minn, A., Ghersi-Egea, J.-F., Perrin, R., Leininger, B. and Siest, G. (1991) Drug metabolizing enzymes in the brain and cerebral microvessels. Brain Res. Rev. 16, 65-82.
257. Kalaria, R.N. and Harik, S.I. (1987) Blood-brain barrier monoamine oxidase: enzyme characterization in cerebral microvessels and other tissues from six mammalian species, including humans. J. Neurochem. 49, 856-864.
258. Betz, A.L. and Goldstein. G.W. (1981) Developmental changes in metabolism and transport properties of capillaries isolated from rat brain. J. Physiol. 312, 365-376.
259. Lai, F.M., Berkowitz, B. and Spector, S. (1978) Influence of age on brain vascular and cardiovascular monoamine oxidase activty in the rat. Life Sci. 22, 2051-2056.
260. Inomata, K., Yoshioka, T., Nasu, F. and Mayahara, H. (1984) Ultracytochemical studies of capillary endothelial cells in the rat central nervous system. Acta Anal. 118, 243-248.
261. Roba, J., Cavalier, R., Cordi, A., Gorissen, H., Herin, M., De Varebeke, J.P., Onkelinx, C., Remacle, M. and Van Dorsser, W. (1986) Milacemide. In: B.S. Meldrum and R.H. Porter (Eds), New Anticonvulsant Drugs, J. Libbey and Co., London, pp. 179-190.
262. Van Dorsser, W., Barris, D., Cordi, A. and Roba, J. (1983) Anticonvulsant activity of milacemide. Arch. Int. Pharmacodyn. 266, 239-249.
263. Saletu, B., Grünberger, J. and Linzmayer, L. (1986) Acute and subacute central nervous system effects of milacemide in elderly people: Double-blind placebo controlled quantitative electroencephalography and psychometric investigations. Arch. Gerentol. Geriat. 5, 165-182.
264. Handelmann, G.E., Nevins, M.E., Mueller, L.L., Arnolde, S.M. and Cordi, A.A. (1989) Milacemide, a glycine prodrug, enhances performance of learning tasks in normal and amnestic rodents. Pharmacol. Biochem. Behav. 34, 823-828.
265. Schwartz, B.L., Hashtroudi, S., Herting, R.L., Handerson, H. and Deutsch, S.I. (1991) Glycine prodrug facilitates memory retrieval in humans. Neurology 41, 1341-1343.
266. de Varebeke, P.J., Cavalier, R., David-Ramacle, M. and Youdim, M.B.H. (1988) Formation of the neurotransmitter glycine from the anticonvulsant milacemide is mediated by brain monoamine oxidase B. J. Neurochem. 50, 1011-1016.
267. Semba, J., Curzon, G. and Patsalos, P.N. (1993) Antiepileptic drug pharmacokinetics and neuropharmacokinetics in individual rats by repetitive withdrawal of blood and cerebrospinal fluid: milacemide. Br. J. Pharmacol. 108, 1117-1124.
268. Yu, P.H. and Davis, B.A. (1990) Some pharmacological implications of MAO-mediated deamination of branched aliphatic amines: 2-propyl-1-aminopentane and N-(2-propylpentyl)glycinamide as valproic acid precursors. J. Neurol. Transm. Suppl. 32, 89-92.
269. Yu, P.H., Davis, B.A., Boulton, A.A. and Zuo, D.M. (1994) Deamination of aliphatic amines by type B monoamine oxidase and semicarbazide-sensitive amine oxidase; pharmacological implications. J. Neural. Transm. Suppl. 41, 397-406.
270. Yu, P.H. and Davis, B.A. (1991) Simultaneous delivery of valproic acid and glycine to the brain. Deamination of 2-propylpentylglycinamide by monoamine oxidase B. Mol. Chem. Neuropathol. 15, 37-49.
271. Coutts, R.T., Baker, G.B., Nazarali, A.J., Rao, T.S., Micetich, R.G. and Hall, T.W. (1985) Prodrugs of trace amines. In: A.A. Boulton, L. Maitre, P.R. Bieck and P. Riederer (Eds), Neuropsychopharmacology of the Trace Amines, Humana Press, Clifton, NJ, pp. 175-180.
272. Baker, G.B., Coutts, R.T. and Rao, T.S. (1987) Neuropharmacological and neurochemical properties of N-(2-cyanoethyl)-2-phenylethylamine, a prodrug of 2-phenylethylamine. Br. J. Pharmacol. 92, 243-255.
273. Rao, T.S., Baker, G.B. and Coutts, R.T. (1987) Pharmacokinetic and neurochemical studies of N-propargyl-2-phenylethylamine, a prodrug of 2-phenylethylamine. Naunyn-Schmiedeberg's Arch. Pharmacol. 336, 25-32.
274. Rao, T.S., Baker, G.B. and Coutts. R.T. (1987) N-(3-Chloropropyl)phenylethylamine as a possible prodrug of β-phenylethylamine: Studies in the rat brain. Prog. Neuro-Psychopharmacol. Biol. Psychiatr. 11, 301-308.
275. Rao, T.S., Baker, G.B. and Coutts, R.T. (1987) N,N-Dipropargyl-2-phenylethylamine, a potential prodrug of 2-phenylethylamine: Neurochemical and neuropharmacological studies in rat. Brain Res. Bull. 19, 47-55.
276. Lupia, R.H., Ferencz, N., Lertora, J.J.L., Aggarwal, S.K., George, W.J. and Agrawal, K.C. (1993) Comparative pharmacokinetics of two prodrugs of zidovudine in rabbits: Enhanced levels of zidovudine in brain tissue. Antimicrob. Agents Chemother. 37, 818-824.
277. Smith, Q.R. (1993) Drug delivery to brain and the role of carrier-mediated transport. In: L.R. Drewes and A.L. Betz (Eds), Frontiers in Cerebral Vascular Biology: Transport and Its Regulation. Plenum Press, New York, pp. 83-100.